Filtered By:
Specialty: Urology & Nephrology
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 95 results found since Jan 2013.
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
CONCLUSIONS: In patients with recurrence after BCG therapy, sequential intravesical gem/doce is an effective and well-tolerated alternative to early cystectomy. Patients with BCG relapsing disease are more likely to respond to additional intravesical gem/doce. Further investigation with a prospective trial is imperative.PMID:37690933 | DOI:10.1016/j.urolonc.2023.06.018
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Kendrick Yim Kevin Melnick Sarah L Mott Filipe L F Carvalho Affan Zafar Timothy N Clinton Matthew Mossanen Graeme S Steele Michelle Hirsch Natalie Rizzo Chin-Lee Wu Kent W Mouw Matthew Wszolek Keyan Salari Adam Feldman Adam S Kibel Michael A O'Donnell Mar Source Type: research
Sequential intravesical gemcitabine and docetaxel for treatment-na ïve and previously treated intermediate-risk nonmuscle invasive bladder cancer
CONCLUSIONS: In this retrospective review of a heterogenous population of patients with intermediate-risk NMIBC, Gem/Doce was an effective and well-tolerated adjuvant therapy. Further prospective evaluation in this setting is needed.PMID:37442741 | DOI:10.1016/j.urolonc.2023.06.017
Source: Urologic Oncology - July 13, 2023 Category: Urology & Nephrology Authors: Ian M McElree Joanna Orzel Reid Stubbee Ryan L Steinberg Sarah L Mott Michael A O'Donnell Vignesh T Packiam Source Type: research
Management of metastatic hormone-sensitive prostate cancer - Current treatment options, criteria for prgoression and switch of therapy
Aktuelle Urol. 2023 May 26. doi: 10.1055/a-2055-0869. Online ahead of print.ABSTRACTBased on convincing data with an increase in overall survival (OS), the current national and international European Guidelines (S3, ESMO, EAU) recommend a combination therapy with ADT plus Docetaxel or plus the next-generation antiandrogens abiraterone (plus prednisone/prednisolone), apalutamide or enzalutamide as standard treatment for mHSPC patients with a good performance status (ECOG 0-1). Abiraterone received approval only for use in patients with newly diagnosed (de novo) high-risk mHSPC. There is no restrictive approval status for do...
Source: Aktuelle Urologie - May 26, 2023 Category: Urology & Nephrology Authors: Kurt Miller Source Type: research
Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis
CONCLUSIONS: The findings of this preliminary cost-effectiveness analysis are novel in that they highlight a well tolerated, efficacious drug that is less expensive than the traditional gold standard therapy. In modern medicine, we are more often challenged by agents with marginally increased efficacy but at significantly higher costs; gemcitabine-docetaxel represents a rare entity which is a success for both patients and healthcare systems alike.PMID:37127478 | DOI:10.1016/j.urolonc.2023.04.005
Source: Urologic Oncology - May 1, 2023 Category: Urology & Nephrology Authors: Laura Bukavina Spencer Bell Vignesh T Packiam Marc Smaldone Philip Abbosh Robert Uzzo Alexander Kutikov Andres F Correa Diana E Magee Source Type: research
Relationships of body composition and adipocytokines with outcomes in metastatic castration-resistant prostate cancer patients receiving docetaxel chemotherapy
Asian J Androl. 2023 Jan 6. doi: 10.4103/aja2022104. Online ahead of print.ABSTRACTWe evaluated the relationships of body composition and serum adipocytokine levels with progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel. The medical records of mCRPC patients who received docetaxel between January 2011 and December 2015 at Fudan University Shanghai Cancer Center (Shanghai, China) were reviewed. The following body composition parameters were calculated using computed tomography: skeletal muscle index (SMI), visceral adipose tissue...
Source: Asian Journal of Andrology - January 11, 2023 Category: Urology & Nephrology Authors: Jun-Hong Li Xing-Ming Zhang Xiao-Jie Bian Wei-Jie Gu Fang-Ning Wan Bo Dai Ding-Wei Ye Source Type: research
